Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Nov 3;16(11):e0252848. doi: 10.1371/journal.pone.0252848

Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency

Jeffrey R Haswell 1,2,#, Kaia Mattioli 2,3,#, Chiara Gerhardinger 3,4, Philipp G Maass 5,6, Daniel J Foster 1,2, Paola Peinado 7, Xiaofeng Wang 8, Pedro P Medina 7, John L Rinn 9, Frank J Slack 1,*
Editor: Romi Gupta10
PMCID: PMC8565776  PMID: 34731163

Abstract

Although many long non-coding RNAs (lncRNAs) exhibit lineage-specific expression, the vast majority remain functionally uncharacterized in the context of development. Here, we report the first described human embryonic stem cell (hESC) lines to repress (CRISPRi) or activate (CRISPRa) transcription during differentiation into all three germ layers, facilitating the modulation of lncRNA expression during early development. We performed an unbiased, genome-wide CRISPRi screen targeting thousands of lncRNA loci expressed during endoderm differentiation. While dozens of lncRNA loci were required for proper differentiation, most differentially expressed lncRNAs were not, supporting the necessity for functional screening instead of relying solely on gene expression analyses. In parallel, we developed a clustering approach to infer mechanisms of action of lncRNA hits based on a variety of genomic features. We subsequently identified and validated FOXD3-AS1 as a functional lncRNA essential for pluripotency and differentiation. Taken together, the cell lines and methodology described herein can be adapted to discover and characterize novel regulators of differentiation into any lineage.

Introduction

The advent of deep sequencing technology has revealed the extensive and widespread nature of transcription across the human genome, with ~80% being transcribed at some point during development [1]. Given that less than 2% of the human genome encodes for protein-coding genes, there exists a vast and expanding network of non-coding RNAs, including long non-coding RNAs (lncRNAs), which are broadly defined as transcripts greater than 200 nucleotides in length with no apparent protein-coding function. Unlike other non-coding RNA families such as microRNAs and Piwi-interacting RNAs, lncRNAs display a wide variety of functions, acting as scaffolds, decoys, and guides in both the nucleus and cytoplasm [2].

Recently, a handful of lncRNAs have emerged as major regulators of key biological processes, including proliferation [3], pluripotency [4], and differentiation [5,6]. Expression profiling of lncRNAs during different stages of development has revealed highly tissue-specific and context-dependent expression, supporting their roles as potential developmental regulators [7]. Despite these preliminary observations, only a small fraction of lncRNAs have been characterized, both in terms of biological function as well as mechanism of action. Given that there are over 17,000 predicted lncRNA loci in the human genome [8], large-scale screens are necessary for elucidating functional lncRNAs. However, a robust, unbiased approach for genome-wide identification of developmentally relevant lncRNAs in human embryonic stem cells (hESCs) has yet to be described.

While the emergence of CRISPR gene editing has revolutionized scalable and cost-effective genetic screens, hESCs and lncRNAs both present a unique set of challenges for perturbing gene expression on a high-throughput scale. Notably, CRISPR editing in hESCs has proven more difficult than in immortalized cell lines, for several reasons. First, Cas9-induced double-stranded breaks have been shown to cause acute toxicity in hESCs in a P53-dependent manner [9]. In addition, hESCs have low transfection efficiencies [10] and demonstrate pervasive transgene silencing during development [11], making it difficult to stably express Cas9 throughout the course of differentiation.

Given their non-coding nature, lncRNAs are difficult to functionally disrupt using small deletions generated by traditional CRISPR-Cas9 methods [12]. Furthermore, while RNAi screens have identified biologically relevant lncRNAs during development [13], they exhibit more off-target effects [14], and are unable to effectively target lncRNAs localized to the nucleus [15]. CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) address the challenges of RNAi and represent effective tools for probing the function of lncRNAs [16]. These methods use catalytically-dead Cas9 (dCas9) proteins fused to effector domains to either repress (CRISPRi) or activate (CRISPRa) expression by targeting the transcription start site (TSS) of genes. While previous groups have constructed dCas9 stem cell lines that maintain expression during either endoderm [17], mesoderm [18], or ectoderm [19] differentiation, a dCas9-expressing hESC line that maintains stable targeting of both coding and non-coding genes during differentiation into all three primary germ layers has not yet been reported.

Here, we successfully developed CRISPRi and CRISPRa hESC lines that demonstrate robust repression and activation, respectively, of lncRNAs as well as protein-coding genes. These are the first reported CRISPR-dCas9 hESC lines to effectively modulate gene expression during differentiation into all three primary germ layers. We used our CRISPRi line to perform a genome-wide screen during definitive endoderm differentiation, identifying and validating several lncRNA loci that control pluripotency and regulate essential endoderm pathways. Furthermore, using our hits from the screen, we developed an unsupervised learning approach to predict the potential mechanisms of action of lncRNA loci based on select genomic features. Taken together, our study establishes an approach that can be scaled across multiple lineages, allowing for a high-throughput method for identifying functional, developmentally relevant lncRNAs.

Materials and methods

H1 hESC cell culture

We acquired H1 (WA01) hESCs from the University of Wisconsin (WiCell). We cultured H1 cells in mTeSR1 media (STEMCELL Technologies) on Matrigel-coated plates and changed media daily. We passaged the cells every 5–7 days, using Gentle Cell Dissociation Reagent (GCDR) or ReLeSR (STEMCELL Technologies).

Generation of dCas9-KRAB/VP64 stable hESCs

To generate dCas9-KRAB-GFP and dCas9-VP64-GFP cell lines, we infected H1 hESCs with lentivirus containing dCas9-KRAB or dCas9-VP64 fused to GFP (via a T2A peptide cleavage linker). We obtained the dCas9-VP64-GFP construct from Addgene (#61422) and generated the dCas9-KRAB-GFP construct by cloning the KRAB cassette into the BamHI and NheI sites of the dCas9-VP64-GFP plasmid. Following infection, we sorted cells for GFP and plated sparsely (20,000 cells/well in 6-well plates) with 10 μM ROCK inhibitor (Y-27632) to obtain single-cell-derived isogenic colonies. Clones were tracked daily, picked manually using a P200 pipette tip, expanded, and tested for dCas9 expression via Western blot using a Cas9 antibody (CST; mouse mAb #14697). To generate the dox-inducible dCas9-KRAB-mCherry cell line, we nucleofected H1 hESCs with the pAAVS1-NDi-CRISPRi (Gen1) vector [20] along with AAVS1 TALEN pair plasmids [20]. Following nucleofection, cells were selected for using 25 μg/mL Geneticin (Life Technologies), then seeded out and expanded using the same methods described above. dCas9-KRAB expression was induced by adding 2 μg/mL doxycycline to the mTeSR1 media.

Endoderm, mesoderm, and ectoderm lineage induction

We used the STEMdiff Definitive Endoderm kit, STEMdiff Early Mesoderm kit, and SMADi Neural Induction kit to induce endoderm, mesoderm, and ectoderm differentiation, respectively. All kits are from STEMCELL Technologies, and differentiation was induced following the manufacturer’s protocol.

RT-qPCR

We isolated RNA using the Direct-zol Miniprep RNA kit (Zymo) with the DNase treatment step. RNA was quantified and reverse transcribed using oligo(dT)20 primers and the SuperScript IV kit (ThermoFisher). RT-qPCR was performed on the LightCycler 480 II instrument (Roche). Reactions were performed in triplicate, and gene expression was normalized to RPL19. Error bars represent standard deviation of the mean. P values were calculated using an unpaired t-test.

Flow cytometry and staining

hESCs and differentiated cells were harvested for staining or flow cytometry using GCDR. Cells were washed twice with 500 μL cold FBS stain buffer (BD #554656), fixed in 250 μL Cytofix fixation buffer (BD #554655) for 15 min at 4°C, and washed twice with 500 μL cold FBS stain buffer. Cells were then stained (if necessary) with extracellular antibody markers for 30 min in the dark at 4°C, washed twice with 500 μL cold FBS stain buffer. For subsequent intracellular staining, cells were washed twice with 500 μL cold 1X permeabilization buffer (BioLegend #421002), resuspended in 100 μL cold 1X permeabilization buffer, and incubated with intracellular antibody markers for 30 min in the dark at 4°C. Prior to flow cytometry analysis, stained cells were washed twice with 500 μL cold 1X permeabilization buffer and resuspended in 500 μL cold FBS stain buffer. A list of antibodies used in this study can be found in the STAR Methods. Cells were analyzed using the FACSymphony (BD), and sorted using the FACSAria (BD).

lncRNA categorization

We downloaded the lncRNA annotation file from GENCODE v25 [8]. We then removed any lncRNAs found to have a conserved open reading frame longer than 100 amino acids via phyloCSF [21], thus assuring that we were analyzing bona fide non-coding RNAs. Finally, we classified lncRNAs into the following categories: (1) intergenic, defined as lncRNAs whose gene starts and ends were both > 1000 bp away from an annotated protein-coding gene, (2) promoter-overlapping, defined as lncRNAs whose gene starts were within 1000 bp of a protein-coding gene start, (3) transcript-overlapping, defined as lncRNAs whose transcripts overlapped a protein-coding transcript (given they were not promoter-overlapping), and (4) gene nearby, defined as lncRNAs that did not physically overlap any protein-coding genes, but had a protein-coding gene start or gene end within 1000 bp of its gene start or gene end.

RNA-seq analysis

We isolated RNA from each lineage (two replicates each) using the Direct-zol Miniprep RNA kit (Zymo) with DNase treatment. We synthesized cDNA and performed Illumina paired end 75bp sequencing. We used the cutadapt program to trim adaptors and low-quality bases off of RNA-seq reads [22]. We then used kallisto [23] to pseudo-align and quantify reads to the GENCODE v25 transcriptome (in hg19 assembly coordinates). As DIGIT was not included in GENCODE v25, we manually added the transcript sequence that was described in Daneshvar et al. [5]. After reads were mapped, we performed differential expression analysis of transcripts using sleuth [24]. We separately tested for differential expression between hESCs and definitive endoderm and hESCs and early mesoderm using likelihood ratio tests. For gene-level quantifications, we summed all transcript counts for a given gene.

Gene ontology enrichment analysis

Gene ontology (GO) enrichment analysis was obtained from the Gene Ontology Consortium [25,26], using the PANTHER Classification System (pantherdb.org). Significantly enriched pathways were determined using Fisher’s Exact test with the Bonferroni correction for multiple testing.

Tissue-specificity calculation

We calculated tissue-specificity across the three lineages (hESCs, endoderm, and mesoderm) using the tau metric [27], which has been shown to be robust to biases arising from low expression. Tau is calculated as follows:

τ=i=1n(1-xi^)n-1;xi^=ximax1in(xi)

where xi is the expression of a transcript in lineage i and n is the number of total lineages (here, 3). Thus, tau calculates the average difference between the expression of a transcript in a given lineage and its maximal expression across all lineages, meaning “ubiquitous” transcripts will have tau values close to zero while “lineage-specific” transcripts will have tau values close to one.

TSS assignment

To assign TSSs to transcripts, we relied on the FANTOM5 CAGE-associated transcriptome (FANTOM-CAT) annotations [28], which sought to accurately define the 5’ ends of human lncRNAs. If the transcript was explicitly assigned a TSS in FANTOM-CAT, as was the case for 46% of transcripts, we used the FANTOM-CAT assigned TSS. Otherwise, if the transcript was within 400 bp of an annotated CAGE TSS on the same strand, which was the case for an additional 26% of transcripts, we assigned the transcript the closest same-stranded CAGE TSS. For all other transcripts (28%), we used the GENCODE-annotated 5’ end of the transcript as the TSS.

CRISPRi library design

We included all 12,611 lncRNA transcripts expressed at ≥ 0.1 tpm in either hESCs, endoderm, or mesoderm. We also included a set of 24 literature-curated positive control transcripts that had been previously shown to be required for endoderm differentiation and 261 other highly differentially-expressed protein-coding genes (S2 Table). We used the GPP sgRNA Designer tool to design sgRNAs targeting the TSSs of the included transcripts (after re-assigning TSSs by the rules above) [29,30]. We assigned the top 10 sgRNAs to each TSS according to the ranking rules used by the GPP tool, which, briefly, prioritizes sgRNAs by distance to the TSS, a lack of off-targets, and predicted site chromatin accessibility [30]. To create negative control sgRNAs, we randomly sampled 500 of our designed sgRNAs and scrambled each one 10 times, making sure to eliminate any that we were able to BLAT to the human genome (parameters used: -stepSize = 5 -minScore = 0 -minIdentity = 0) for a total of 5000 scrambled sgRNAs. Finally, as some transcripts had the same TSS, or very close TSSs, we consolidated any duplicate sgRNAs in the library. All told, our CRISPRi library contained 111,801 unique sgRNAs. Of the 106,801 targeting sgRNAs, 93.2% were not predicted to have any off-targets near protein-coding TSSs, and 74.7% were not predicted to have any off-targets near non-coding gene TSSs, which is similar to previously described lncRNA-targeting CRISPRi libraries [31].

CRISPRi library cloning

The sgRNA library was synthesized by Twist Biosciences. We then amplified the library using emulsion PCR and cloned it into the pCRISPRia-v2 vector as previously described [32]. We then packaged the library into lentivirus in HEK293T cells, also as previously described [32].

CRISPRi endoderm differentiation screen

To perform the screen, we infected dCas9-KRAB-GFP cells with the lentivirally-packaged sgRNA library at an MOI < 0.3 and selected in 1 μg/mL puromycin. We then used the STEMdiff Definitive Endoderm kit (STEMCELL Technologies) to induce differentiation, according to the manufacturer’s instructions. We isolated a sample of “Day Zero” cells to assess initial representation of sgRNAs. Five days post-differentiation induction, we harvested and stained cells for FOXA2 and SOX17, two markers of definitive endoderm. Specifically, we stained batches of 5 million cells with 20 μL FOXA2-APC (Miltenyi Biotec #130-107-774) and 4 μL SOX17-PE (Miltenyi Biotec #130-111-032). We used FACS to sort populations into undifferentiated (FOXA2/SOX17 double negative) and differentiated (FOXA2/SOX17 double positive) populations. We additionally sorted each population by BFP expression, as BFP was indicative of effective CRISPRi repression. For all populations, we isolated DNA from all cells using QIAamp columns (Qiagen), following the manufacturer’s instructions and adding a de-crosslinking step (resuspended cells in 180 μL Buffer ATL and 20 μL proteinase K, incubated at 56°C for 1 h, then 90°C for 1 h, then proceeded with standard QIAamp protocol). Following DNA isolation, we PCR amplified the sgRNA region as previously described [32]. We prepared sequencing libraries as previously described [31], and performed high-throughput Illumina single end 50bp DNA sequencing to assess sgRNA counts. We performed two separate biological replicates of the entire screen.

CRISPRi screen sgRNA filtering

We performed 3 consecutive filtering steps to remove noisy sgRNAs. First, we filtered sgRNAs to those that had ≥ 5 cpm in both Day Zero replicates (S5C Fig in S1 Appendix), resulting in a set of 76,091 sgRNAs. Then, we further filtered that set of sgRNAs to those that had ≥ 1 cpm in both undifferentiated replicates (Fig 3C), resulting in a set of 57,384 sgRNAs. Finally, we further filtered that set of sgRNAs, removing any sgRNAs targeting TSSs that did not have ≥ 3 sgRNAs that met the first two filters, resulting in a final set of 55,804 sgRNAs (Fig 3D).

CRISPRi screen analysis

We calculated log2 foldchanges between undifferentiated counts and differentiated counts for all 111,801 sgRNAs using DESeq2 [33], including replicate as a term in the model to correct for batch effects. We then used CRISPhieRmix [34] on the DESeq2-calculated log2 foldchanges to find significant hits in our CRISPRi screen, after filtering the data as described in the previous section. We ran CRISPhieRmix with default parameters, using the filtered set of 2,690 scrambled sgRNAs as negative control inputs. As CRISPhieRmix only outputs an FDR per targeted TSS and no effect size, we estimated the effect size of each TSS to be the average of its top 3 most enriched (highest log2 foldchange) sgRNAs, as has been done previously [31].

ENCODE expression and splicing efficiency quantification

We used ENCODE RNA-seq data to determine maximum transcript expression and splicing efficiency across a panel of 12 ENCODE cell lines (A549, GM12878, H1, HT1080, HUES64, IMR-90, K562, MCF-7, NCI-H460, SK-MEL-5, SK-N-DZ, and SK-N-SH). For both analyses, we downloaded the raw fastqs (after filtering out any samples that did not pass ENCODE’s internal audits) and aggregated reads corresponding to technical replicates. For the expression analysis, we mapped the reads to the GENCODE v25 transcriptome (in hg19 assembly coordinates) using kallisto [23]. For the splicing efficiency analysis, we used kallisto to map reads to the same transcriptome, this time including all unspliced gene sequences as additional “transcripts”. We calculated splicing efficiency for each gene as previously described; briefly, genes whose reads map entirely to the unspliced “transcript” will have a splicing efficiency of 0, whereas genes whose reads map only to spliced transcripts will have a splicing efficiency of 1 [35].

Genomic feature aggregation

We aggregated a variety of genomic features for both lncRNAs and mRNAs. We aggregated the following features using GENCODE v25 annotations: (1) maximum RNA transcript length (i.e., length of the spliced transcript) across all transcripts for a gene, (2) maximum number of exons across all transcripts for a gene, (3) mean transcript GC content across all transcripts for a gene, and (4) DNA locus length (i.e., genomic distance from the transcript TSS to the 3’ end of the transcript, which includes introns). We aggregated the following features using FANTOM5 data: (1) number of FANTOM5-annotated TSSs (active in any tissue) [36] within 100 bp of the GENCODE-annotated transcript TSS (on the same strand), (2) number of FANTOM5-annotated enhancers (active in any tissue) [37] within 1 Mb of the transcript, and (3) distance from the TSS to the closest FANTOM5-annotated enhancer (active in any tissue). We aggregated the following features using the PhastCons 46-way sequence alignment [38]: (1) mean conservation score of the 200bp region surrounding the transcript TSS (maximum across all transcripts for a gene), and (2) mean conservation score across all exonic sequences in the transcript (maximum across all transcripts for a gene). We also determined the distance from the TSS to the closest endoderm-specific enhancer as defined by Loh et al., 2014 (their S5 Table) as well as the distance from the TSS to the closest definitive endoderm H3K27ac, H3K27me3, H3K4me2, and H3K4me3 peaks (peak calls downloaded from the Cistrome database) [39].

GWAS

We downloaded the list of GWAS Catalog (all associations, v.1.0.2) from https://www.ebi.ac.uk/gwas/docs/file-downloads [40]. We then found the hg19 coordinates for each SNP using the 1000Genomes annotation [41]. We limited our analyses to SNPs associated with cancers of tissues that arise from the endoderm lineage (a list of traits used can be found in S3 Table). We then found the closest endoderm-cancer associated SNP to every gene.

Feature-based clustering analysis

We normalized our data such that each feature had a mean of 1 and a standard deviation of 1 and performed k-means clustering on this highly dimensional standardized data (using 2 clusters and standard parameters in sklearn’s KMeans function). We visualized results using a t-SNE plot (with 2 components and standard parameters in sklearn’s TSNE function).

Results

Generation of CRISPRi and CRISPRa hESC lines that stably express dCas9 throughout differentiation into all three germ layers

We sought to develop the tools necessary to perform genome-wide perturbation screens throughout differentiation. To this end, we established CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) systems in human embryonic stem cells (hESCs) that could effectively repress or activate, respectively, gene targets in all three primary germ layers: ectoderm, endoderm, and mesoderm. Specifically, we infected H1 (WA01) hESCs with lentiviral GFP constructs containing EF1-α promoter-driven dCas9 fused to either a Krüppel-associated box (KRAB) repressor domain (Fig 1A) or a VP16 tetramer (VP64) activation domain (S1A Fig in S1 Appendix). We chose the EF1-α promoter due to its diminished propensity for silencing in embryonic stem cells [42], and screened hundreds of isogenic clones for constitutive expression of dCas9-KRAB or dCas9-VP64 during early differentiation. We identified clones that stably expressed dCas9 in an undifferentiated state after several passages, as well as throughout the course of definitive endoderm and early mesoderm differentiation (Fig 1B and S1B Fig in S1 Appendix), as well as neural progenitor cell (ectoderm) differentiation (Fig 1C and S1C Fig in S1 Appendix). Fluorescence-activated cell sorting (FACS) analysis of our clones showed >99% GFP expression in each germ layer (Fig 1D and S1D Fig in S1 Appendix), suggesting uniform and stable dCas9 expression. In addition to our constitutively-expressed clones, we used a TALEN-assisted gene-trap approach to insert a dox-inducible dCas9-KRAB-mCherry cassette into the AAVS1 safe harbor locus in H1 cells (S2A Fig in S1 Appendix). Similarly, this isogenic hESC line displayed expression of dCas9-KRAB in each primary germ layer (S2B-S2D Fig in S1 Appendix).

Fig 1. Establishing a CRISPRi cell line that maintains repression during differentiation.

Fig 1

(A) Lentiviral GFP construct containing dCas9-KRAB driven by the EF1-α promoter. (B) Western blot of dCas9-KRAB over the course of definitive endoderm and early mesoderm differentiation. (C) Western blot of dCas9-KRAB over the course of neural progenitor cell (ectoderm) differentiation. (D) FACS analysis of GFP expression for undifferentiated and differentiated dCas9-KRAB-GFP line compared to H1 cells. (E) FACS staining of targeted mRNA genes in undifferentiated and differentiated dCas9-KRAB-GFP cells. (F) RT-qPCR expression of targeted lncRNAs in undifferentiated dCas9-KRAB-GFP hESCs. *** = p < 0.001 by an unpaired t-test. (G) RT-qPCR expression of targeted lncRNAs during endoderm, mesoderm, and ectoderm differentiation in dCas9-KRAB-GFP cells. ** = p < 0.01, *** = p < 0.001 by an unpaired t-test.

After confirming stable expression of dCas9-KRAB and dCas9-VP64 in our isogenic lines, we evaluated the knockdown and activation efficiency of our CRISPRi and CRISPRa systems, respectively. We cloned single guide RNAs (sgRNAs) into the pCRISPRia-v2 expression vector [43], targeting the transcription start site (TSS) of both protein-coding genes and long non-coding RNA (lncRNAs). After lentiviral sgRNA transduction, puromycin selection, and induction of differentiation of our isogenic lines, we observed robust knockdown (Fig 1E–1G and S2E Fig in S1 Appendix) or activation (Fig S1E in S1 Appendix) of targeted mRNAs and lncRNAs, as measured by FACS staining and RT-qPCR, respectively. We consistently measured knockdown levels greater than 99%, and activation levels that exceeded 4-fold upregulation.

Taken together, these isogenic lines represent the first reported hESC cell lines to stably express dCas9-KRAB or dCas9-VP64 and effectively repress or activate target genes throughout the course of differentiation into the three primary germ layers. Thus, we have successfully engineered cell lines which can be employed to perform genome-wide gene perturbation throughout differentiation.

Genome-wide profiling of lncRNAs during early differentiation into endoderm and mesoderm

We next sought to define a subset of candidate lncRNAs that may be acting in definitive endoderm differentiation based on gene expression patterns. To this end, we performed RNA-sequencing on two biological replicates from undifferentiated hESCs, day 5 definitive endoderm, and day 5 early mesoderm (which is derived from the same mesendodermal lineage as definitive endoderm), and quantified lncRNA and mRNA expression at the transcript and gene levels across all samples (Fig 2A and S3A Fig in S1 Appendix; see Materials and methods).

Fig 2. lncRNAs are differentially and specifically expressed across hESCs, definitive endoderm, and early mesoderm.

Fig 2

(A) Heatmap showing the expression, standardized per sample (column z-score) for the 10,000 most highly expressed protein-coding genes (left) and all 8,190 lncRNA genes with a minimum gene tpm of 0.1 in at least 1 sample (right). Genes (rows) and samples (columns) are hierarchically clustered using the correlation as the distance metric. (B) Average expression in each lineage of lineage marker genes POU5F1 (OCT4), NANOG, EOMES, GATA6, and T. Gray bars correspond to 90% confidence intervals, calculated across 2 biological replicates. (C) Top 10 gene ontology terms significantly enriched in either endoderm (top) or mesoderm (bottom) compared to undifferentiated hESCs. Size of dots is inversely proportional to the Bonferroni-corrected p-value; all plotted terms have p-values < 0.05. (D) Count of transcripts expressed at a minimum of 0.1 tpm in either hESCs, endoderm, or mesoderm, broken up into either protein-coding genes (blue) or lncRNAs (red). The lncRNAs are further classified based on their genomic proximity to other transcripts, as outlined in the schematic to the left. (E) Volcano plots showing the log2 expression fold-change between endoderm and hESCs (left) and mesoderm and hESCs (right) for all lncRNA transcripts. Horizontal lines define a q-value cut-off of 0.05. (F) Tissue-specificity of genes calculated across hESCs, endoderm, and mesoderm, for all lncRNA genes (top) and all mRNA genes (bottom) as well as a set of curated human transcription factors (middle) from Lambert et al. [44]. Gene-level tpms were used.

We confirmed that expected markers were highly expressed in their respective lineages, such as POU5F1 (OCT4) and NANOG in hESCs, EOMES and GATA6 in definitive endoderm, and T in early mesoderm (Fig 2B). Gene ontology analysis of differentially expressed genes in endoderm or mesoderm compared to undifferentiated hESCs revealed enrichment of the expected biological pathways (Fig 2C; see methods).

We found that 8,190 lncRNA genes corresponding to 12,611 lncRNA transcripts were expressed at ≥ 0.1 tpm in at least one of the three lineages (undifferentiated hESCs, endoderm, or mesoderm) (Fig 2D and S3B Fig in S1 Appendix; S1 Table). While 3,702 (29%) of these lncRNA transcripts were intergenic (further than 1000bp away from a protein-coding transcript), the majority of these lncRNA transcripts were either very close to or overlapping protein-coding genes (Fig 2D). Additionally, 4,158 lncRNA transcripts were differentially expressed between either hESCs and definitive endoderm or hESCs and mesoderm (Fig 2E). The majority of these lncRNA transcripts (2,939 (71%)) were uniquely differentially expressed in only one of the lineages. On average, lncRNAs were more specifically expressed than mRNAs when examining expression profiles across the three lineages (Fig 2F; see methods). Moreover, lncRNAs were also more specifically expressed than known human transcription factors (as defined by [44]) across these three lineages (Fig 2F).

Collectively, these data represent a robust overview of both the coding and non-coding transcriptome in hESCs, definitive endoderm, and early mesoderm, and define a subset of lncRNAs that are putatively functioning in hESC differentiation.

CRISPRi screen to identify lncRNA loci essential for proper differentiation

We next used our RNA-seq data to design a comprehensive CRISPRi screen of lncRNAs expressed during endoderm differentiation. Specifically, we included all 12,611 lncRNA transcripts expressed at ≥ 0.1 tpm in either undifferentiated hESCs, definitive endoderm, or early mesoderm. We additionally included a set of 24 literature-curated positive control transcripts (e.g. FOXA2, SOX17, GATA6, EOMES) that are known to be required for endoderm differentiation, as well as 261 additional highly differentially expressed protein-coding transcripts. The full list of transcripts targeted by our library can be found in S2 Table.

CRISPRi induces knockdown by targeting a transcriptional repressor domain (KRAB) to the TSSs of genes. Because TSSs are often misannotated for lowly-expressed transcripts [28], we refined the annotated TSSs of genes in our screen using a set of high-confidence TSSs defined by the FANTOM5 consortium [45] (Fig S3C and S3D in S1 Appendix; see methods). We consolidated these TSSs (some of which corresponded to multiple transcripts) into a list of 10,852 unique TSSs. We then designed 10 single guide RNAs (sgRNAs) targeting each of these TSSs using the optimized GPP sgRNA Designer tool, which minimizes off-target effects while maximizing knockdown efficiency [29,30]. Finally, we sampled 500 of these targeting sgRNAs and randomly scrambled them 10 times to create a set of 5,000 non-targeting negative control sgRNAs. In total, after removing duplicates, our CRISPRi sgRNA library included 111,801 unique sgRNAs (Fig 3A).

Fig 3. CRISPRi screen identifies lncRNA loci that reproducibly affect endoderm differentiation.

Fig 3

(A) Number of TSSs targeted and corresponding unique sgRNAs in the CRISPRi library. (B) Schematic overview of the CRISPRi screen. The sgRNA library was packaged into lentivirus and transduced into dCas9-KRAB-GFP hESCs, which were then induced to undergo endoderm differentiation. Day Zero cells were collected to measure initial representation of the sgRNA library. After five days, the cells were sorted for endoderm markers SOX17 and FOXA2, and populations of differentiated and undifferentiated cells were collected, as shown in the representative FACS plot. PE = phycoerythrin. APC = allophycocyanin. (C) Kernel density estimate plot showing the counts per million in the undifferentiated populations for both replicate 1 and replicate 2. Horizontal and vertical lines define a cpm of 1 in each replicate; color bar indicates densities of sgRNAs. (D) Number of TSSs targeted and corresponding unique sgRNAs after filtering steps that are used in downstream analyses. (E) Distribution of sgRNA enrichments (DESeq2 log2 fold-change of undifferentiated counts compared to differentiated counts, including a batch term) for scrambled negative control sgRNAs (gray) and positive control targeting sgRNAs (green). P-value shown is from a one-sided Mann Whitney test. (F) Plot showing the transcript enrichment score (average DESeq2 log2 fold-change of top 3 most enriched sgRNAs) and CRISPhieRmix global FDR values for each lncRNA transcript (gray), positive control transcript (green), and differentially expressed mRNA transcript (white) tested. Hit lncRNA transcripts that do not have another gene TSS within 1000 bp of their own TSS are further highlighted (dark gray). Horizontal line defines an FDR cut-off of 0.1.

We transduced the lentiviral pooled CRISPRi library into undifferentiated dCas9-KRAB-GFP hESCs and selected with puromycin. After 4–5 days of selection and expansion (S4A Fig in S1 Appendix), we isolated cells from this “Day Zero” population to assess the overall sgRNA distribution (Fig 3B). We then induced definitive endoderm differentiation using the STEMdiff Definitive Endoderm Kit (see methods). After five days, we stained cells for FOXA2 and SOX17 expression—two markers of definitive endoderm—and used FACS to sort high-confidence populations of FOXA2+/SOX17+ and FOXA2-/SOX17- cells (Fig 3B and S4B-S4D Fig in S1 Appendix). Finally, we characterized the sgRNA representation in each of these populations using targeted sequencing.

To ensure reproducibility of our results and limit false positives, we performed two independent biological replicates of the screen. In each replicate, endoderm differentiation was extremely efficient and undifferentiated cells were sorted conservatively (S4D and S4E Fig in S1 Appendix). As expected, replicates were generally correlated, with most noise presenting as sampling noise among low count sgRNAs in the undifferentiated replicates (S5A Fig in S1 Appendix).

We next performed two important filtering steps to address the inherent noise of the screen. First, we required sgRNAs to have ≥ 5 counts per million (cpm) in both Day Zero replicates to limit any noise due to poor initial sgRNA representation (S5B Fig in S1 Appendix). Second, since we gated FOXA2-/SOX17- undifferentiated cells conservatively, a subset of sgRNAs were present in only one of the two undifferentiated population replicates (Fig 3C). Thus, we required sgRNAs to have ≥ 1 cpm in both undifferentiated replicates. Finally, we required that targeted TSSs have ≥ 3 sgRNAs that meet these criteria. Together, these filtering steps resulted in a set of 55,804 reproducibly represented sgRNAs targeting 9,771 TSSs (90% of all TSSs included in the library) (Fig 3D and S5C and S5D Fig in S1 Appendix).

We then used DESeq2 to calculate the enrichment (i.e. log2 fold change of counts) of these 55,804 filtered sgRNAs in the undifferentiated FOXA2-/SOX17- populations compared to the differentiated FOXA2+/SOX17+ populations. Given the sgRNA count variance that was introduced by performing two conservative biological replicates of the screen (S5E Fig in S1 Appendix), we included a term for batch (replicate) in the DESeq2 model when calculating log2 fold changes. As expected, sgRNAs targeting positive controls had significantly higher log2 fold changes than scrambled sgRNAs (Fig 3E).

To further validate the quality of our screen, we compared our results to a previous lncRNA-targeting growth screen performed in iPSC cells (CRiNCL) [31]. We reasoned that sgRNAs targeting lncRNAs that affect iPSC growth, as found by CRiNCL, should affect growth in hESCs as well, and therefore drop out of our differentiated samples. Indeed, among the 1117 sgRNAs that overlapped between our screen and CRiNCL, we found that sgRNA drop out correlated between the two screens (S5F Fig in S1 Appendix).

To determine which TSSs were highly likely to contribute to proper endoderm differentiation, we used CRISPhieRmix, a tool which was specifically developed to address issues unique to CRISPRi/a screens, such as variable sgRNA efficiency [34]. The Bayesian hierarchical mixture modelling strategy employed by CRISPhieRmix allows for more statistical power in large-scale pooled CRISPRi screens while controlling false discovery rates [46]. We confirmed that our data met the assumptions employed by CRISPhieRmix—namely, that the majority of targeting sgRNAs resemble negative control sgRNAs (S5G Fig in S1 Appendix) and that sgRNAs targeting positive control genes follow a mixture distribution composed of only a subset of sgRNAs that work (S5H Fig in S1 Appendix). We then applied CRISPhieRmix to the set of 55,804 filtered sgRNAs (S3 Table; see Materials and methods).

In total, 73 TSSs out of the 9,771 TSSs tested were significantly enriched in the undifferentiated population at an FDR < 0.1 (Fig 3F). As expected, many of the most significant hits were positive control mRNAs, including SOX17, FOXA2, EOMES, and GATA6. However, it is important to note that several positive control genes were not recovered in the screen. Thus, while our conservative FACS gating resulted in a list of 73 TSSs that are reproducibly and significantly associated with proper endoderm differentiation, we lack the power to infer the number of putatively functional lncRNAs due to a high false negative rate. Of the 73 significant TSSs, 60 corresponded to lncRNA loci, and 26 of these lncRNA TSSs were not within 1000 bp of another gene TSS (Fig 3F).

Collectively, these data show that our genome-wide CRISPRi screen was able to reproducibly recapitulate expected biological signal, and suggest that, at minimum, dozens of lncRNA loci may be required for proper endoderm differentiation. We provide the results of our screen for all targeted lncRNAs and mRNAs as a resource to the community (S2 and S3 Tables).

Validation of individual screen hits

Following our CRISPRi screen, we validated several control (mRNA) hits, lncRNA loci hits, and lncRNA loci non-hits (S4 Table). To do this, we selected 22 sgRNAs present in the screening library and tested them each individually. All sgRNAs were cloned and subsequently transduced into our dCas9-KRAB-GFP hESC line using the pCRISPRia-v2 expression vector [32]. Following puromycin selection, we induced infected cells into definitive endoderm for five days, then stained for FOXA2/SOX17 to assess differentiation efficiency. In addition, we performed RT-qPCR to determine knockdown efficiency of each individual sgRNA.

For each individually tested sgRNA, we calculated a validation enrichment score based on the ratio of undifferentiated cells to differentiated cells five days post endoderm differentiation. We observed a significant (p = 0.002) correlation between screen sgRNA enrichment score and the validation enrichment score (Fig 4A).

Fig 4. CRISPRi screen reveals several lncRNA loci required for endoderm differentiation.

Fig 4

(A) Correlation of the validation sgRNA score and the screen sgRNA score for all 22 sgRNAs validated, colored by whether the sgRNAs target control mRNA hits (green), lncRNA hits (black), or lncRNA non-hits (white). Validation scores were calculated according to the formula outlined. Example validation data for 8 sgRNAs targeting 2 control mRNA and 2 lncRNA hits are shown in (B)-(F); the full dataset is in S4 Table. r = Spearman’s rho, p = Spearman p-value, n = # sgRNAs. (B) RT-qPCR expression of mRNA SOX17 (sgRNAs #1 and #2) or EOMES (sgRNAs #3 and #4) during endoderm differentiation using either a scrambled negative control sgRNA (light gray bars) or a targeting sgRNA (green bars). Labeled sgRNA numbers correspond to those outlined in (A). *** = p-value < 0.001 by an unpaired t-test. (C) RT-qPCR expression of lncRNA RP11-120D5.1 (sgRNAs #5 and #6) or RP11-222K16.2 (sgRNAs #7 and #8) during endoderm differentiation using either a scrambled negative control sgRNA (light gray bars) or a targeting sgRNA (dark gray bars). Labeled sgRNA numbers correspond to those outlined in (A). * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.001 by an unpaired t-test. (D) FACS staining of scrambled negative control sgRNAs during endoderm differentiation, with percentages of differentiated cells (top right box) and undifferentiated cells (bottom left box) labeled. Three separate endoderm differentiation time courses were performed to validate the 8 outlined sgRNAs. Scrambled sgRNA #1 was run as a negative control for targeting sgRNAs #1, #7, and #8; scrambled sgRNA #2 was run as a negative control for targeting sgRNAs #2, #3, and #4; scrambled sgRNA #3 was run as a negative control for targeting sgRNAs #5 and #6. (E) FACS staining of mRNA-targeting sgRNAs #1–4 during endoderm differentiation, with percentages of differentiated cells (top right box) and undifferentiated cells (bottom left box) labeled. (F) FACS staining of lncRNA-targeting sgRNAs #5–8 during endoderm differentiation, with percentages of differentiated cells (top right box) and undifferentiated cells (bottom left box) labeled.

We observed significant knockdown for the majority of our targets (Fig 4B and 4C; S4 Table), confirming the efficiency and robustness of our dCas9-KRAB-GFP cell line. As expected, sgRNAs targeting mRNA hits (e.g. SOX17, EOMES) resulted in severe loss-of-differentiation phenotypes (Fig 4E; S4 Table), as demonstrated by reduction of SOX17 and/or FOXA2 expression at the protein level (via FACS). While knockdown of our lncRNA loci hits resulted in more subtle phenotypes, we observed consistent reduction of endoderm markers compared to scrambled sgRNA controls (Fig 4F; S4 Table). Interestingly, targeted knockdown of certain lncRNA loci resulted in reduced expression of one specific marker (e.g. reduced SOX17 expression in RP11-222K16.2 knockdown), suggesting a potential mechanism of regulation. Taken together, we were able to individually validate mRNA and lncRNA loci hits resulting from our genome-wide CRISPRi screen. While we validated a subset of hits and non-hits, further work is needed to validate the full set of lncRNA loci targets described in this study.

Common features of lncRNA hits

After validating the results of the screen, we next sought to determine what features, if any, were common to the hit lncRNA loci that were required for differentiation (Fig 5A and S6 Fig in S1 Appendix; see methods). Given the potentially high false negative rate of our screen, we focused on comparing our hit lncRNA loci to a set of “stringent non-hit” lncRNA loci: targeted lncRNA TSSs with ≥ 9 filtered sgRNAs represented and a CRISPhieRmix FDR of > 0.9. All told, our list of stringent non-hit lncRNA loci contained 158 unique genes (S5 Table). We found that our hit lncRNA loci were significantly closer to known endoderm cancer-associated SNPs than stringent non-hit lncRNA loci (Fig 5B; S5 and S6 Tables). In particular, three of our hit lncRNA loci—RP11-867G2.8, RP11-541P9.3, and VLDLR-AS1—contain endoderm cancer-associated SNPs in their gene bodies. While VLDLR-AS1 is known to play important roles in liver and esophageal cancer [47,48], RP11-541P9.3 and RP11-867G2.8 remain uncharacterized.

Fig 5. lncRNA hits are associated with certain genomic features.

Fig 5

(A) List of genomic features analyzed and their associated two-sided Mann Whitney p-values comparing hit lncRNAs vs. stringent non-hit lncRNAs. Features with Benjamini-Hochberg adjusted FDRs of < 0.10 are shown in bold. (B-F) Boxplots showing the distributions of various genomic features outlined in (A) for hit lncRNAs and stringent non-hit lncRNAs. Median value of each distribution is also shown. P-values are from two-sided Mann Whitney tests. (G) Volcano plot showing the RNA-seq results for stringent non-hits (in gray, all biotypes) and hits (colored by biotype as shown above the plot). Horizontal line depicts an FDR cut-off of 0.05 for significant differential expression between endoderm and hESCs.

We found that our hit lncRNA loci had significantly more nearby FANTOM5-defined TSSs (on the same strand) than stringent non-hit lncRNA loci (Fig 5C). Our hit lncRNAs had significantly higher expression in our endoderm RNA-seq data than stringent non-hit lncRNAs (Fig 5D). Hit lncRNAs also had higher maximum expression values across a panel of 12 ENCODE cell lines (Fig 5F) and were more efficiently spliced than stringent non-hit lncRNAs across this same panel of ENCODE cell lines (Fig 5E; see methods).

Interestingly, while expression levels and differential expression levels were higher in hit lncRNAs compared to stringent non-hit lncRNAs, we did not observe a significant enrichment of hits among differentially expressed transcripts (two-sided Fisher’s exact test odds ratio = 1.27, p-value = 0.36). Indeed, the proportion of hit lncRNAs to stringent non-hit lncRNAs is similar within differentially expressed and non-differentially expressed transcripts (19% in both cases) (Fig 5G). Thus, lncRNA expression profiles are not necessarily predictive of biological function of lncRNA loci. Taken together, these data suggest that while some features are associated with hits, loss-of-function screens remain pivotal in assessing the functionality of lncRNA loci.

Inferring the mechanisms of action of hit lncRNA loci

As CRISPRi induces the formation of heterochromatin around a guide RNA’s target site, any DNA regulatory activity that the target locus may possess is shut down along with RNA transcription [49]. Thus, using CRISPRi, it is impossible to distinguish lncRNAs acting through DNA-based mechanisms (e.g. as enhancers) from lncRNAs acting through RNA-based mechanisms (e.g. as scaffolds or decoys). We sought to predict which of our lncRNA loci hits, if any, were most likely to have RNA-based mechanisms of action.

While the number of characterized lncRNAs is growing, there remain very few whose mechanisms of action are well-characterized. We therefore could not rely on supervised learning approaches to perform mechanistic predictions, as we currently lack a trusted set of training data. We previously showed that known functional lncRNAs with likely RNA-based mechanisms resemble mRNAs across a variety of genomic features including expression patterns, splicing efficiency, and conservation [35]. Thus, we used unsupervised methods to cluster genes based on a set of 11 general genomic features (Fig 6A; see Materials and methods).

Fig 6. Using k-means clustering of 11 genomic features to find candidate functional RNA molecules.

Fig 6

(A) List of the 11 genomic features used in clustering analysis across 33,817 genes. (B) t-SNE visualization of the data matrix outlined in (A), colored by k-means cluster assignment. Plot shows a sub-sample of the data: 1000 randomly-sampled lncRNAs and 1000 randomly-sampled mRNAs. (C) Same t-SNE as in (A), now colored by biotype, where gray dots are lncRNAs and green dots are mRNAs. The 3 “gold standard” lncRNAs (XIST, NEAT1, and MALAT1) are highlighted and outlined in black. (D) Subset of the same t-SNE in (A) and (B), now showing only lncRNAs included in the screen, colored by their cluster assignment. Significant hits in either cluster are outlined in black. Hits assigned to cluster 1 are annotated.

We used k-means to cluster this highly dimensional dataset into 2 clusters and visualized the results using the t-distributed stochastic neighbor embedding (t-SNE) dimensionality reduction approach (Fig 6B). As expected, cluster 1 contained primarily lncRNAs while cluster 2 contained primarily mRNAs (Fig 6C). While the data exists on a continuum of all considered features, cluster separation was driven primarily by splicing efficiency, maximum expression, and exon conservation (S7 Fig in S1 Appendix). Three “gold standard” lncRNAs known to exhibit RNA-based mechanisms (XIST, NEAT1, and MALAT1) all clustered with mRNAs (Fig 6C), which is consistent with our previous work [35]. We found that while 6 lncRNA hits clustered with mRNAs (VLDLR-AS1, PCBP-AS1, LAMTOR5-AS1, HOXC-AS1, LINC00623, and FOXD3-AS1), the majority of our lncRNA hits did not (Fig 6D). Moreover, for each of these 6 lncRNAs, there is experimental evidence for an RNA-based phenotype, either through lncRNA knockdown approaches (VLDLR-AS1 and LAMTOR5-AS1) [47,48,50] or, in 4 cases (HOXC-AS1, FOXD3-AS1, PCBP-AS1 and LINC00623), also including lncRNA ectopic overexpression approaches [5154].

Taken together, these data suggest that most lncRNA hits resulting from our CRISPR screen are likely acting as DNA regulatory elements, but a subset may be playing a role in endoderm differentiation through RNA-based mechanisms. To facilitate future validation work, the results of our feature-based clustering analysis are available in S7 Table.

Characterization of FOXD3-AS1 as a regulator of pluripotency and endoderm pathways

Finally, we investigated the potential function of one our lncRNA hits that we predicted to have an RNA-based mechanism of action, FOXD3-AS1 (CRISPhieRmix FDR = 0.026). Of the 6 lncRNA gene hits predicted to have RNA-based mechanisms of action, FOXD3-AS1 showed the highest level of differential expression between endoderm and hESCs in our RNA-seq data (Fig 7A). However, FOXD3-AS1 follows an unexpected expression pattern: it is one of the most highly enriched lncRNAs in undifferentiated hESCs and demonstrates significant downregulation during endoderm and mesoderm differentiation (Fig 7B; S1 Table). Given this unexpected expression pattern, we were interested in elucidating the role of FOXD3-AS1 in potentially regulating pluripotency and differentiation.

Fig 7. FOXD3-AS1 expression and knockdown in hESCs.

Fig 7

(A) Log2 fold change between expression in hESCs and endoderm for all hit lncRNA transcripts in the screen whose loci were predicted to have RNA-based mechanisms of action (Fig 6). * = significant differential expression, sleuth q-value < 0.05. The LAMTOR5-AS1 hit TSS targeted in our screen could not resolve between 6 different LAMTOR5-AS1 transcripts (GENCODE transcript numbers in parantheses), and as such they are all plotted here. (B) RT-qPCR expression time course during definitive endoderm differentiation of H1 hESCs. (C) RT-qPCR expression of FOXD3-AS1 21 days post infection of H1 hESCs with FOXD3-AS1 shRNAs. *** = p < 0.001 by an unpaired t-test. (D) Phase-contrast images of H1 hESCs infected with FOXD3-AS1 shRNAs. Images were taken 21 days post infection. (E) RT-qPCR expression of pluripotency/differentiation genes 21 days post infection of H1 hESCs with FOXD3-AS1 shRNAs. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 by an unpaired t-test. (F-H) FACS staining of day 5 definitive endoderm cells (F), day 5 early mesoderm cells (G), or day 12 neural progenitor cells (H) infected with scrambled shRNA or FOXD3-AS1 shRNA #1. Cells were fixed and stained with antibodies against FOXA2 and SOX17 (F), VIM and CD49e (G), or NES and PAX6 (H).

Because the FOXD3-AS1 promoter overlaps the promoter of FOXD3 (a transcription factor required for self-renewal of stem cells), we used multiple shRNAs to specifically target the lncRNA (Fig 7C). While maintaining hESCs in stem cell media, visible differentiation occurred (Fig 7D), with RT-qPCR and FACS analysis confirming complete loss of pluripotency markers at 18 days post infection (S8A Fig in S1 Appendix). We also observed strong upregulation of several key endoderm factors (Fig 7E), including GATA6, FOXA2, EOMES, and CXCR4 in response to FOXD3-AS1 knockdown. Following upregulation of endoderm factors, we observed an eventual loss of pluripotency markers (S8A Fig in S1 Appendix). A time course knockdown of FOXD3-AS1 (S8B Fig in S1 Appendix) showed early induction of EOMES, along with reduction of FOXD3 expression within 48 h. To test whether FOXD3-AS1 was required for differentiation into other lineages, we induced early mesoderm or ectoderm differentiation in hESCs following knockdown of FOXD3-AS1. We observed significant reduction in properly differentiated cells in each lineage using two different shRNAs (Fig 7F–7H and S8C-S8E Fig in S1 Appendix), suggesting that loss of FOXD3-AS1 results in dysregulation of pluripotency pathways required for early embryogenesis.

Following knockdown experiments, we cloned and overexpressed FOXD3-AS1 in undifferentiated hESCs and observed reduced expression of several endoderm factors (S8F Fig in S1 Appendix), consistent with the role of FOXD3-AS1 as repressing endoderm pathways. Taken together, these experiments support FOXD3-AS1 as a novel pluripotency factor required for pluripotency via repression of the endoderm lineage. Moreover, our RNA knockdown results support the prediction that FOXD3-AS1 exerts its function through RNA-based mechanisms. Our results are in agreement with a recent publication [55] which found that the FOXD3-AS1 lncRNA is localized to the cytoplasm and affects pluripotency of hESCs through modulating Wnt signaling, an essential pathway required for definitive endoderm differentiation [56]. Thus, the CRISPRi screening approach outlined herein, coupled with additional bioinformatic analyses, revealed developmentally relevant lncRNA loci, a subset of which likely act as functional RNAs.

Discussion

Here, we report the first described set of hESC cell lines that can maintain dCas9 expression (and successfully modulate target gene expression) throughout differentiation into all three germ layers (Fig 1, and S1 and S2 Figs in S1 Appendix). These cell lines can be used for CRISPRi screens, as we have shown in this work, as well as CRISPRa screens. Although we focus on early endoderm differentiation in this study, we also show that these cell lines maintain dCas9 expression throughout mesoderm and ectoderm differentiation. Thus, the methodology described can be adapted to discover novel regulators (both coding and non-coding) of differentiation into any lineage. The cells we have engineered are available to the community upon request. Additionally, we provide all data produced in this work—including the RNA-seq data, the results of the CRISPRi screen, and the clustering analysis—as resources to the community.

Our CRISPRi screen reproducibly identified known endoderm factors as top hits, including FOXA2 and SOX17, as well as EOMES, GATA6, and GSC. Moreover, we identified 73 lncRNA loci, including the previously reported endoderm regulator DIGIT [5]. We used a conservative approach to identify hits: we performed two independent biological replicates of the screen and performed conservative FACS gating of differentiated and undifferentiated populations. We speculate that we have missed a number of functional lncRNAs, due to both the conservative nature of our screen, as well as the fact that lncRNAs are known to often exert quite subtle effects on gene expression [57]. Nevertheless, our approach yielded a list of dozens of lncRNA loci that are likely required for proper endoderm differentiation (S3 Table), most of which are entirely uncharacterized. Further validation and functional studies are needed to characterize the specific mechanisms by which these lncRNA loci regulate endoderm differentiation, whether via direct regulation of endoderm factors (e.g. DIGIT) or via regulation of pluripotency (e.g. FOXD3-AS1).

Of these lncRNA hits, only 16 of them are intergenic (greater than 1000 bp away from any other gene). Thus, the majority of lncRNA hits we identified are either physically overlapping a protein-coding gene or within 1000 bp of a protein-coding gene promoter; this proximity makes it likely that some sgRNAs in our screen were also affecting expression of the protein-coding genes proximal to these lncRNAs. However, there is precedence for this class of lncRNAs to play bona fide roles in early development. Indeed, divergent lncRNAs (which are included in our “promoter overlap” biotype) have been found to play particularly important roles in pluripotency and differentiation [58]. In addition, a literature analysis of lncRNA hits near protein-coding gene TSSs revealed that only 10 out of 34 overlapped with known regulators of hESC differentiation (S9 Fig in S1 Appendix), providing a high confidence list of potential protein-coding genes primed for further investigation.

Using CRISPRi to knockdown lncRNA loci precludes us from inferring RNA-based mechanisms of action for hits, as the heterochromatin recruited by dCas9-KRAB will shut down DNA regulatory elements as well as transcription. In order to infer lncRNAs with likely RNA-based mechanisms of action, we aggregated a variety of genomic datasets and performed unsupervised clustering. Based on previous work [35], we expected lncRNAs with RNA-based mechanisms to cluster with mRNAs. Using this method, we predicted that only 6 of our screen hits were likely to exhibit RNA-based mechanisms of action (Fig 6D). We note that it is difficult to robustly evaluate our approach without more gold standard examples of lncRNAs that act as bona fide functional RNAs, and we also note that lncRNAs can have multiple mechanisms of action. As additional data becomes available, more sophisticated models will likely be necessary, and experimental validation of predictions will always be essential. However, our clustering approach provides a foundational set of candidate functional lncRNAs to prioritize for future validation (S7 Table).

We validated a top hit from our screen, FOXD3-AS1, and found that it is required for maintaining hESC pluripotency. FOXD3-AS1 is significantly differentially expressed between hESCs and endoderm, but surprisingly, it is upregulated ~300-fold in hESCs compared to endoderm. Our data show that FOXD3-AS1 is required for pluripotency by acting as a repressor of endoderm factors. We speculate that repression of FOXD3-AS1 at the incorrect developmental time point results in aberrant expression of endoderm factors, which disrupts the pluripotent state of hESCs. Subsequent downregulation of stemness factors (OCT4, NANOG, SOX2) leads to loss of pluripotency (S8A Fig in S1 Appendix), which ultimately results in improper differentiation into endoderm, as well as other lineages. Despite having promoter overlap with the known pluripotency regulator FOXD3, shRNAs targeting the FOXD3-AS1 transcript mimicked the sgRNA phenotypes observed in the screen, pointing towards an RNA-based mechanism of action, as our k-means clustering predicted (Fig 6D).

Finally, our work underscores the importance of performing functional screens to characterize lncRNAs. While we found that some features were associated with lncRNA hits (Fig 5), most features examined were not significantly different between hits and non-hits. Importantly, we also observed that expression levels are not necessarily predictive of biological function, as the proportion of hit lncRNA loci was roughly equal between loci harboring differentially expressed lncRNAs and non-differentially expressed lncRNAs (Fig 5H). Thus, loss-of-function screens are paramount to characterizing the vast non-coding transcriptome and its role in development and differentiation. Taken together, our CRISPRi and CRISPRa cell lines described herein can serve as a resource for functional screens in any of the three primary germ layers, identifying and elucidating the role of both coding and non-coding genes in development.

Supporting information

S1 Table. RNA-seq lncRNA expression in hESCs, endoderm, and mesoderm.

(TXT)

S2 Table. CRISPRi screen sgRNA counts in each population.

(TXT)

S3 Table. CRISPhieRmix results per targeted transcript in screen.

(TXT)

S4 Table. Validation results for the 22 sgRNAs tested individually.

(TXT)

S5 Table. Genomic features of all lncRNAs targeted in the screen.

(TXT)

S6 Table. List of cancers/traits from endoderm-derived tissues.

(TXT)

S7 Table. Clustering results of all annotated lncRNAs and mRNAs.

(TXT)

S1 Appendix. Document containing S1-S9 Figs.

(DOCX)

S1 Raw images. Labeled unadjusted/uncropped images for all blots/gels included in manuscript.

(PDF)

Acknowledgments

The authors thank members of the Slack lab for technical help (Allison Baker, Christos Miliotis, Emanuelle Grody, Jihoon Lim, Soomi Lee, Tanvi Saxena); the Harvard Medical School Department of Immunology’s Flow Cytometry Core Facility for technical support (Chad Araneo, Felisha Lopez, Daniela Gutierrez); and Scott Younger, Martin Sauvageau, Mo Mandegar, Max Horlbeck, Kaveh Daneshvar, and Ryan Genga for advice and guidance.

Data Availability

The accession number for the data reported in this paper is NCBI GEO: GSE137584. All code to reproduce analysis is available at link: https://github.com/kmattioli/2019__lncRNA_CRISPRi. All processed data are available within the manuscript’s Supporting information files.

Funding Statement

This work was funded by the US National Institutes of Health (NIH) grant P01GM099117, and by the National Science Foundation Graduate Research Fellowship under the grant DGE1144152 (J.R.H. and K.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136: 629–641. doi: 10.1016/j.cell.2009.02.006 [DOI] [PubMed] [Google Scholar]
  • 2.Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. Annu Rev Biochem. 2012;81: 145–166. doi: 10.1146/annurev-biochem-051410-092902 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gasri-Plotnitsky L, Ovadia A, Shamalov K, Nizri-Megnaji T, Meir S, Zurer I, et al. A novel lncRNA, GASL1, inhibits cell proliferation and restricts E2F1 activity. Oncotarget. 2017;8: 23775–23786. doi: 10.18632/oncotarget.15864 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25: 69–80. doi: 10.1016/j.devcel.2013.03.002 [DOI] [PubMed] [Google Scholar]
  • 5.Daneshvar K, Pondick JV, Kim B-M, Zhou C, York SR, Macklin JA, et al. DIGIT Is a Conserved Long Noncoding RNA that Regulates GSC Expression to Control Definitive Endoderm Differentiation of Embryonic Stem Cells. Cell Rep. 2016;17: 353–365. doi: 10.1016/j.celrep.2016.09.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Jiang W, Liu Y, Liu R, Zhang K, Zhang Y. The lncRNA DEANR1 facilitates human endoderm differentiation by activating FOXA2 expression. Cell Rep. 2015;11: 137–148. doi: 10.1016/j.celrep.2015.03.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15: 7–21. doi: 10.1038/nrg3606 [DOI] [PubMed] [Google Scholar]
  • 8.Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47: D766–D773. doi: 10.1093/nar/gky955 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24: 939–946. doi: 10.1038/s41591-018-0050-6 [DOI] [PubMed] [Google Scholar]
  • 10.Moore JC, van Laake LW, Braam SR, Xue T, Tsang S-Y, Ward D, et al. Human embryonic stem cells: genetic manipulation on the way to cardiac cell therapies. Reprod Toxicol. 2005;20: 377–391. doi: 10.1016/j.reprotox.2005.04.012 [DOI] [PubMed] [Google Scholar]
  • 11.Liew C-G, Draper JS, Walsh J, Moore H, Andrews PW. Transient and stable transgene expression in human embryonic stem cells. Stem Cells. 2007;25: 1521–1528. doi: 10.1634/stemcells.2006-0634 [DOI] [PubMed] [Google Scholar]
  • 12.Zhu S, Li W, Liu J, Chen C-H, Liao Q, Xu P, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34: 1279–1286. doi: 10.1038/nbt.3715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature. 2011;477: 295–300. doi: 10.1038/nature10398 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9: 57–67. doi: 10.1038/nrd3010 [DOI] [PubMed] [Google Scholar]
  • 15.Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res. 2016;44: 863–877. doi: 10.1093/nar/gkv1206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154: 442–451. doi: 10.1016/j.cell.2013.06.044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Genga RMJ, Kernfeld EM, Parsi KM, Parsons TJ, Ziller MJ, Maehr R. Single-Cell RNA-Sequencing-Based CRISPRi Screening Resolves Molecular Drivers of Early Human Endoderm Development. Cell Rep. 2019;27: 708–718.e10. doi: 10.1016/j.celrep.2019.03.076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Eskildsen TV, Ayoubi S, Thomassen M, Burton M, Mandegar MA, Conklin BR, et al. MESP1 knock-down in human iPSC attenuates early vascular progenitor cell differentiation after completed primitive streak specification. Dev Biol. 2019;445: 1–7. doi: 10.1016/j.ydbio.2018.10.020 [DOI] [PubMed] [Google Scholar]
  • 19.Liu Y, Yu C, Daley TP, Wang F, Cao WS, Bhate S, et al. CRISPR Activation Screens Systematically Identify Factors that Drive Neuronal Fate and Reprogramming. Cell Stem Cell. 2018;23: 758–771.e8. doi: 10.1016/j.stem.2018.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mandegar MA, Huebsch N, Frolov EB, Shin E, Truong A, Olvera MP, et al. CRISPR Interference Efficiently Induces Specific and Reversible Gene Silencing in Human iPSCs. Cell Stem Cell. 2016;18: 541–553. doi: 10.1016/j.stem.2016.01.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lin MF, Jungreis I, Kellis M. PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions. Bioinformatics. 2011;27: i275–82. doi: 10.1093/bioinformatics/btr209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 2011;17: 10. doi: 10.14806/ej.17.1.200 [DOI] [Google Scholar]
  • 23.Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016;34: 525–527. doi: 10.1038/nbt.3519 [DOI] [PubMed] [Google Scholar]
  • 24.Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nat Methods. 2017;14: 687–690. doi: 10.1038/nmeth.4324 [DOI] [PubMed] [Google Scholar]
  • 25.Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: tool for the unification of biology. Nat Genet. 2000;25: 25–29. doi: 10.1038/75556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res. 2019;47: D330–D338. doi: 10.1093/nar/gky1055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Kryuchkova-Mostacci N, Robinson-Rechavi M. A benchmark of gene expression tissue-specificity metrics. Brief Bioinformatics. 2017;18: 205–214. doi: 10.1093/bib/bbw008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hon C-C, Ramilowski JA, Harshbarger J, Bertin N, Rackham OJL, Gough J, et al. An atlas of human long non-coding RNAs with accurate 5’ ends. Nature. 2017;543: 199–204. doi: 10.1038/nature21374 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32: 1262–1267. doi: 10.1038/nbt.3026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34: 184–191. doi: 10.1038/nbt.3437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Liu SJ, Horlbeck MA, Cho SW, Birk HS, Malatesta M, He D, et al. CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells. Science. 2017;355. doi: 10.1126/science.aah7111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Horlbeck MA, Gilbert LA, Villalta JE, Adamson B, Pak RA, Chen Y, et al. Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation. Elife. 2016;5. doi: 10.7554/eLife.19760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15: 550. doi: 10.1186/s13059-014-0550-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Daley TP, Lin Z, Lin X, Liu Y, Wong WH, Qi LS. CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens. Genome Biol. 2018;19: 159. doi: 10.1186/s13059-018-1538-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Melé M, Mattioli K, Mallard W, Shechner DM, Gerhardinger C, Rinn JL. Chromatin environment, transcriptional regulation, and splicing distinguish lincRNAs and mRNAs. Genome Res. 2017;27: 27–37. doi: 10.1101/gr.214205.116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.FANTOM Consortium and the RIKEN PMI and CLST (DGT), Forrest ARR, Kawaji H, Rehli M, Baillie JK, de Hoon MJL, et al. A promoter-level mammalian expression atlas. Nature. 2014;507: 462–470. doi: 10.1038/nature13182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, et al. An atlas of active enhancers across human cell types and tissues. Nature. 2014;507: 455–461. doi: 10.1038/nature12787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15: 1034–1050. doi: 10.1101/gr.3715005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12: R83. doi: 10.1186/gb-2011-12-8-r83 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 2019;47: D1005–D1012. doi: 10.1093/nar/gky1120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526: 68–74. doi: 10.1038/nature15393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Norrman K, Fischer Y, Bonnamy B, Wolfhagen Sand F, Ravassard P, Semb H. Quantitative comparison of constitutive promoters in human ES cells. PLoS One. 2010;5: e12413. doi: 10.1371/journal.pone.0012413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, et al. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014;159: 647–661. doi: 10.1016/j.cell.2014.09.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, et al. The human transcription factors. Cell. 2018;172: 650–665. doi: 10.1016/j.cell.2018.01.029 [DOI] [PubMed] [Google Scholar]
  • 45.Lizio M, Harshbarger J, Shimoji H, Severin J, Kasukawa T, Sahin S, et al. Gateways to the FANTOM5 promoter level mammalian expression atlas. Genome Biol. 2015;16: 22. doi: 10.1186/s13059-014-0560-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Bodapati S, Daley TP, Lin X, Zou J, Qi LS. A benchmark of algorithms for the analysis of pooled CRISPR screens. Genome Biol. 2020;21: 62. doi: 10.1186/s13059-020-01972-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Takahashi K, Yan IK, Wood J, Haga H, Patel T. Involvement of extracellular vesicle long noncoding RNA (linc-VLDLR) in tumor cell responses to chemotherapy. Mol Cancer Res. 2014;12: 1377–1387. doi: 10.1158/1541-7786.MCR-13-0636 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Chen Y, Liu L, Li J, Du Y, Wang J, Liu J. Effects of long noncoding RNA (linc-VLDLR) existing in extracellular vesicles on the occurrence and multidrug resistance of esophageal cancer cells. Pathol Res Pract. 2019;215: 470–477. doi: 10.1016/j.prp.2018.12.033 [DOI] [PubMed] [Google Scholar]
  • 49.Thakore PI, D’Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods. 2015;12: 1143–1149. doi: 10.1038/nmeth.3630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Li Z, Zheng J, Xia Q, He X, Bao J, Chen Z, et al. Identification of Specific Long Non-Coding Ribonucleic Acid Signatures and Regulatory Networks in Prostate Cancer in Fine-Needle Aspiration Biopsies. Front Genet. 2020;11: 62. doi: 10.3389/fgene.2020.00062 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Huang C, Hu Y-W, Zhao J-J, Ma X, Zhang Y, Guo F-X, et al. Long Noncoding RNA HOXC-AS1 Suppresses Ox-LDL-Induced Cholesterol Accumulation Through Promoting HOXC6 Expression in THP-1 Macrophages. DNA Cell Biol. 2016;35: 722–729. doi: 10.1089/dna.2016.3422 [DOI] [PubMed] [Google Scholar]
  • 52.Zhao X, Li D, Huang D, Song H, Mei H, Fang E, et al. Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF. Mol Ther. 2018;26: 755–773. doi: 10.1016/j.ymthe.2017.12.017 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 53.Luo T, Gao Y, Zhangyuan G, Xu X, Xue C, Jin L, et al. lncRNA PCBP1-AS1 Aggravates the Progression of Hepatocellular Carcinoma via Regulating PCBP1/PRL-3/AKT Pathway. Cancer Manag Res. 2020;12: 5395–5408. doi: 10.2147/CMAR.S249657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Yan H, Xia JY, Feng FZ. Long non-coding RNA ENST00000457645 reverses cisplatin resistance in CP70 ovarian cancer cells. Genet Mol Res. 2017;16. doi: 10.4238/gmr16019411 [DOI] [PubMed] [Google Scholar]
  • 55.Guo C-J, Ma X-K, Xing Y-H, Zheng C-C, Xu Y-F, Shan L, et al. Distinct Processing of lncRNAs Contributes to Non-conserved Functions in Stem Cells. Cell. 2020;181: 621–636.e22. doi: 10.1016/j.cell.2020.03.006 [DOI] [PubMed] [Google Scholar]
  • 56.Teo AKK, Valdez IA, Dirice E, Kulkarni RN. Comparable generation of activin-induced definitive endoderm via additive Wnt or BMP signaling in absence of serum. Stem Cell Rep. 2014;3: 5–14. doi: 10.1016/j.stemcr.2014.05.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19: 143–157. doi: 10.1038/nrm.2017.104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Luo S, Lu JY, Liu L, Yin Y, Chen C, Han X, et al. Divergent lncRNAs Regulate Gene Expression and Lineage Differentiation in Pluripotent Cells. Cell Stem Cell. 2016;18: 637–652. doi: 10.1016/j.stem.2016.01.024 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Romi Gupta

9 Jul 2021

PONE-D-21-17843

Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency

PLOS ONE

Dear Dr. Slack,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by July 28. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Romi Gupta

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ

4. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have performed well designed and well controlled experiments in the manuscript.

I do not have any suggestions for major experiments for the manuscript.

Two minor suggestions:

1. Hit lncRNA and non hit lncRNA do they have any specific chromatin signature, as authors suggest a major portion of hit lncRNA acts through DNA elements.

2. FOXD3 coding gene promoter do show any change at local chromatin structure in the shRNA KD?

Reviewer #2: In this study “Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency” author developed CRISPRi and CRISPRa hESC lines and demonstrated robust repression and activation, respectively, of lncRNAs as well as protein-coding genes that effectively modulate gene expression that involved hESC lines. Author also developed an unsupervised learning approach to predict the potential mechanisms of action of lncRNA loci based on select genomic features. The current study successfully established an approach that can be applied to multiple lineage specific differentiation processes.

Minor comments.

1. Figure.1 B. the represented western blots are saturated, please replace with another exposure.

2. Figure 1. author encouraged to show the expression of differentiation markers as primary evidence of the model systems.

3. Figure 7C. Author encouraged to show the knockdown FOXD3-AS1 efficiency by western blotting.

4. Author encouraged to study one more lncRNA from Figure 7A.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Suresh Chava

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Nov 3;16(11):e0252848. doi: 10.1371/journal.pone.0252848.r002

Author response to Decision Letter 0


16 Aug 2021

Full response to reviewers is attached in the manuscript data as it contains a plot, but is copy-pasted here for convenience.

Reviewer #1: The authors have performed well designed and well controlled experiments in the manuscript.

I do not have any suggestions for major experiments for the manuscript.

Two minor suggestions:

1. Hit lncRNA and non hit lncRNA do they have any specific chromatin signature, as authors suggest a major portion of hit lncRNA acts through DNA elements.

We thank the reviewer for this suggestion. While we did look to see if our hit lncRNA loci were closer to nearby endoderm enhancers than non-hit loci (Figure S6K), we did not initially look at specific chromatin marks. We have therefore downloaded the ChIP-seq peaks for the 4 chromatin marks studied in definitive endoderm in Loh et al. 2014—H3K27ac, H3K27me3, H3K4me3, and H3K4me2—and determined their locations in relation to our hit lncRNA loci vs. non-hit lncRNA loci. We found that hit lncRNAs were, on average, closer than non-hit lncRNA loci to definitive endoderm H3K4me3 peaks, H3K4me2 peaks, and H3K27ac peaks, though all had only moderate Mann Whitney p-values (minimum 0.073, maximum 0.136). Thus, both promoter marks (H3K4me3 and H3K4me2) and enhancer marks (H3K27ac) are somewhat enriched near hit lncRNA loci, consistent with our conclusion that many of the lncRNA loci may act as DNA elements. The only ChIP-seq profile which did not show any differences between hits and non-hits is H3K27me3, which is expected, as this mark delineates silenced (not actively expressed) regions.

We have added the following plots to Figure S6:

And have updated the Methods section to describe the above analysis: “We also determined the distance from the TSS to the closest endoderm-specific enhancer as defined by Loh et al., 2014 (their Table S5) as well as the distance from the TSS to the closest definitive endoderm H3K27ac, H3K27me3, H3K4me2, and H3K4me3 peaks (peak calls downloaded from the Cistrome database) (Liu et al., 2011).”

2. FOXD3 coding gene promoter do show any change at local chromatin structure in the shRNA KD?

While we did not examine the local chromatin structure of the FOXD3 coding gene promoter upon FOXD3-AS1 shRNA KD, our group is currently exploring the mechanism behind FOXD3-AS1 regulation of pluripotency, including examining changes in chromatin landscape upon FOXD3-AS1 KD. Given that similar phenotypes were observed in both DNA- (CRISPRi) and RNA-based (shRNA) methods of FOXD3-AS1 KD, we believe that FOXD3-AS1 acts as a functional lncRNA as opposed to a DNA element. This hypothesis is supported by the recent study by Guo et al. (2020; cited in our manuscript) that characterized FOXD3-AS1 as acting in the cytoplasm to block the interaction between �-TrCP and phosphorylated �-catenin, leading to suppressed �-catenin degradation and WNT activation. We are currently performing ChIP-seq experiments to examine potential chromatin changes mediated at the FOXD3/FOXD3-AS1 promoter locus and are investigating the role that FOXD3 may play in FOXD3-AS1-mediated control of pluripotency.

Reviewer #2: In this study “Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency” author developed CRISPRi and CRISPRa hESC lines and demonstrated robust repression and activation, respectively, of lncRNAs as well as protein-coding genes that effectively modulate gene expression that involved hESC lines. Author also developed an unsupervised learning approach to predict the potential mechanisms of action of lncRNA loci based on select genomic features. The current study successfully established an approach that can be applied to multiple lineage specific differentiation processes.

Minor comments.

1. Figure.1 B. the represented western blots are saturated, please replace with another exposure.

We thank the reviewer for this suggestion. Unfortunately there are no additional Western blot exposures that were taken, so we are unable to provide those images without performing additional experiments. All authors on this manuscript are no longer in the corresponding authors’ labs, making it difficult to repeat the experiments in a timely manner. However, we are confident that the conclusions from Figure 1B are supported by several additional data points in the paper, including Figure 1D demonstrating maintenance of GFP expression throughout differentiation in all three lineages and Figures 1E-1G demonstrating robust knockdown of both protein-coding (1E) and lncRNA (1F-G) genes. If dCas9-KRAB expression was not maintained over the course of endoderm and mesoderm differentiation, the levels of target gene repression would likely not be as strong.

2. Figure 1. author encouraged to show the expression of differentiation markers as primary evidence of the model systems.

We thank the reviewer for this suggestion. The levels of pluripotency and differentiation markers observed in our engineered lines (both protein-coding and non-coding genes) were similar to those observed in wild-type H1 hESCs, as evidenced by high RT-qPCR expression of lncRNAs in the absence of targeted sgRNAs (Figure 1F-1G), as well as strong protein expression observed by FACS during the screens (Figure S4) and in individual validation experiments (Figure 4).

3. Figure 7C. Author encouraged to show the knockdown FOXD3-AS1 efficiency by western blotting.

We thank the reviewer for the suggestion. Since FOXD3-AS1 does not code for a protein, we are unable to demonstrate knockdown efficiency via Western blotting, and instead showed RT-qPCR to demonstrate efficient knockdown of the RNA transcript.

4. Author encouraged to study one more lncRNA from Figure 7A.

We thank the reviewer for the suggestion. The main purpose of this report is to serve as a resource for the community rather than a deep dive into specific lncRNAs. We are currently investigating several lncRNAs identified from the screen (in addition to FOXD3-AS1) for their role in mediating pluripotency and differentiation. We look forward to sharing those findings in a future publication.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Romi Gupta

27 Aug 2021

Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency

PONE-D-21-17843R1

Dear Dr. Slack,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Romi Gupta

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Romi Gupta

25 Oct 2021

PONE-D-21-17843R1

Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency

Dear Dr. Slack:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Romi Gupta

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. RNA-seq lncRNA expression in hESCs, endoderm, and mesoderm.

    (TXT)

    S2 Table. CRISPRi screen sgRNA counts in each population.

    (TXT)

    S3 Table. CRISPhieRmix results per targeted transcript in screen.

    (TXT)

    S4 Table. Validation results for the 22 sgRNAs tested individually.

    (TXT)

    S5 Table. Genomic features of all lncRNAs targeted in the screen.

    (TXT)

    S6 Table. List of cancers/traits from endoderm-derived tissues.

    (TXT)

    S7 Table. Clustering results of all annotated lncRNAs and mRNAs.

    (TXT)

    S1 Appendix. Document containing S1-S9 Figs.

    (DOCX)

    S1 Raw images. Labeled unadjusted/uncropped images for all blots/gels included in manuscript.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    The accession number for the data reported in this paper is NCBI GEO: GSE137584. All code to reproduce analysis is available at link: https://github.com/kmattioli/2019__lncRNA_CRISPRi. All processed data are available within the manuscript’s Supporting information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES